imipramine

Trade name: tofranil

Small moleculeapproved

Approved

Apr 16, 1959

Imipramine is a tricyclic antidepressant with general pharmacological properties similar to those of structurally related tricyclic antidepressant drugs such as amitriptyline and doxepin. A tertiary amine, imipramine inhibits the reuptake of serotonin more so than most secondary amine tricyclics, meaning that it blocks the reuptake of neurotransmitters serotonin and noradrenaline almost equally. With chronic use, imipramine also down-regulates cerebral cortical β-adrenergic receptors and sensitizes post-synaptic sertonergic receptors, which also contributes to increased serotonergic transmission. It takes approximately 2 - 4 weeks for antidepressants effects to occur. The onset of action may be longer, up to 8 weeks, in some individuals. It is also effective in migraine prophylaxis, but not in abortion of acute migraine attack. Imipramine works by inhibiting the neuronal reuptake of the neurotransmitters norepinephrine and serotonin. It binds the sodium-dependent serotonin transporter and sodium-dependent norepinephrine transporter preventing or reducing the reuptake of norepinephrine and serotonin by nerve cells. Depression has been linked to a lack of stimulation of the post-synaptic neuron by norepinephrine and serotonin. Slowing the reuptake of these neurotransmitters increases their concentration in the synaptic cleft, which is thought to contribute to relieving symptoms of depression. In addition to acutely inhibiting neurotransmitter re-uptake, imipramine causes down-regulation of cerebral cortical beta-adrenergic receptors and sensitization of post-synaptic serotonergic receptors with chronic use. This leads to enhanced serotonergic transmission. Used for relief of symptoms of depression and as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older. May also be used to manage panic disorders, with or without agoraphobia, as a second line agent in ADHD, management of eating disorders, for short-term management of acute depressive episodes in bipolar disorder and schizophrenia, and for symptomatic treatment of postherpetic neuralgia. — NCATS

Clinical trial activity

32 trials · 43 clinical orgs · 27 marketing orgs

Phase 1
5
Phase 2
15
Phase 3
9
Phase 4
5

Earliest trial started Sep 1, 1982 (NCT00000504)

Timeline

1950s

  1. Apr 16, 1959

    Earliest FDA Approval

  2. Apr 16, 1959

    Sanofi-Aventis — NDA Secondary Org

  3. Jun 1, 1959

    Ciba — First NDA Organization

  4. Jun 1, 1959

    Ciba — NDA Organization

  5. Oct 2, 1959

    Novartis — NDA Secondary Org

1970s

  1. Mar 11, 1973

    Specgx Llc — NDA Secondary Org

  2. Jun 27, 1974

    Teva — Marketing Organization

  3. Nov 15, 1974

    Abbott — NDA Secondary Org

  4. Apr 20, 1976

    Sandoz — Marketing Organization

  5. Aug 5, 1977

    Roxane Laboratories — Marketing Organization

  6. Jun 19, 1978

    Alta Pharma — Marketing Organization

  7. Oct 16, 1978

    Watson Pharmaceuticals — Marketing Organization

1980s

  1. Jan 1, 1982

    Earliest Phase 2 Sponsor(trial)

  2. Jan 4, 1982

    Vanguard — Marketing Organization

  3. Feb 10, 1982

    Upsher-Smith Laboratories — Marketing Organization

  4. Apr 5, 1982

    Lederle — Marketing Organization

  5. Apr 5, 1982

    American Cyanamid — Marketing Organization

  6. Oct 21, 1983

    Par Pharmaceuticals — Marketing Organization

  7. Oct 21, 1983

    Strides Pharma Science — Marketing Organization

  8. May 22, 1984

    Mallinckrodt — Marketing Organization

  9. May 22, 1984

    Avon Products — Marketing Organization

  10. May 22, 1984

    Specgx Llc — Marketing Organization

  11. Jan 1, 1985

    Earliest Phase 3 Sponsor(trial)

1990s

  1. Jun 5, 1990

    Sun Pharmaceuticals — Marketing Organization

2000s

  1. Jan 1, 2005

    Sandoz — Earliest Phase 1 Sponsor(trial)

  2. Feb 28, 2008

    Oxford Pharmaceuticals — Marketing Organization

2010s

  1. Mar 11, 2010

    Lupin — Marketing Organization

  2. Mar 11, 2010

    Chartwell Pharmaceuticals — Marketing Organization

  3. Apr 16, 2010

    West-Ward Pharmaceutical — Marketing Organization

  4. Apr 16, 2010

    Hikma — Marketing Organization

  5. Oct 24, 2012

    Leading Pharma Llc — Marketing Organization

  6. Jun 28, 2013

    Mylan — Marketing Organization

  7. Jun 28, 2013

    Rising Pharmaceuticals — Marketing Organization

Indications

Mechanism of action

Approval history

  • approvedPriority reviewApr 16, 1959

Chemistry & pharmacology

Loading structure…

SMILES

CN(C)CCCN1c2ccccc2CCc2ccccc21.CN(C)CCCN1c2ccccc2CCc2ccccc21.O=C(O)c1cc2ccccc2c(Cc2c(O)c(C(=O)O)cc3ccccc23)c1O
Mol. weight
949.21 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Prescription Only

Oral

Yes

Parenteral

No

Topical

No

Black box warning

Sources

Also known as

  • 10,11-dihydro-n,n-dimethyl-5h-dibenz[b,f]azepine-5-propanamine
  • 10,11-dihydro-n,n-dimethyl-5h-dibenz[b,f]azepine-5-propanamine
  • 3-(5h-dibenzo[b,f]azepin-5-yl)-n,n-dimethylpropan-1-amine
  • 5-[3-(dimethylamino)propyl]-10,11-dihydro-5h-dibenz[b,f]azepine
  • 5-[3-(dimethylamino)propyl]-10,11-dihydro-5h-dibenz[b,f]azepine
  • antideprin
  • antideprin
  • imipramin
  • imipramin
  • imipramine
  • imipramine
  • imipramine
  • imipramine
  • imipramine
  • imipramine
  • imipramine
  • imipramine
  • imipramine
  • imipramine
  • imipramine hcl
  • imipramine hcl
  • imipramine hcl
  • imipramine hydrochloride
  • imipramine hydrochloride
  • imipramine hydrochloride
  • imipramine hydrochloride
  • imipramine hydrochloride
  • imipramine pamoate
  • imipramine pamoate
  • imipramine pamoate
  • imipraminum
  • imipraminum
  • imizine
  • imizine
  • irmin
  • irmin
  • janimine
  • janimine
  • melipramine
  • melipramine
  • melipramine
  • n-(gamma-dimethylaminopropyl)iminodibenzyl
  • n-(gamma-dimethylaminopropyl)iminodibenzyl
  • n-(γ-dimethylaminopropyl)iminodibenzyl
  • n-(γ-dimethylaminopropyl)iminodibenzyl
  • pramine
  • pramine
  • praminil
  • prazepine
  • presamine
  • presamine
  • presamine
  • sarimp
  • tofranil
  • tofranil
  • tofranil-pm
  • tofranil-pm

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06778434Phase 2Apr 1, 2025Department of Veteran Affairs
NCT06778824N/AApr 2, 2024Hualien Tzu Chi General Hospital
NCT06312813Phase 2Feb 27, 2024Wright State University
NCT05677295Phase 3Apr 18, 2023Far Eastern Memorial Hospital
NCT05688904Phase 1Jan 19, 2023Wright State University
NCT04863950Phase 2Nov 30, 2021University of Texas, San Antonio
NCT04520217Phase 1Dec 31, 2020Wright State University
NCT04412876Phase 3Aug 1, 2020Far Eastern Memorial Hospital
NCT03960125Early Phase 1 (Phase 1)Jul 31, 2019Wright State University
NCT03122444N/AJun 1, 2017University of Texas, San Antonio
NCT03102645Phase 1May 16, 2017University of Copenhagen
NCT02374567Phase 3Jan 1, 2015Gottfried Wilhelm Leibniz Universität Hannover
NCT01896349N/AApr 1, 2013Federal University of Rio Grande do Sul
NCT01753128Phase 3Dec 1, 2012Mahidol University
NCT01518634Phase 2Jan 1, 2012Aarhus University
NCT01179828Phase 3Jul 1, 2010Aalborg University, University of Bern, University of Zurich
NCT01028014N/AApr 1, 2010Astellas, University of Alabama, Birmingham
NCT01047488Phase 4Feb 1, 2010Nycomed, Pfizer, University of Southern Denmark
NCT01107353N/AAug 1, 2008Novum Pharmaceutical Research Services, Roxane Laboratories
NCT00404755Phase 4Jul 1, 2006Columbia University
Showing 20 of 32 trials
Page 1 / 2

Organizations

Research & Development (43)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Columbia UniversityAcademic/Hospital4321982
Wright State UniversityAcademic/Hospital4422019
National Heart, Lung, and Blood Institute (NHLBI)Government3121982
University of Alabama, BirminghamAcademic/Hospital3131982
Department of Veteran AffairsGovernment2111982
Far Eastern Memorial HospitalAcademic/Hospital2212020
University of CopenhagenAcademic/Hospital2222004
University of Texas, San AntonioAcademic/Hospital2222017
Aalborg UniversityAcademic/Hospital1012010
Aarhus UniversityAcademic/Hospital1112012
AstellasFor profit1012010
Baylor UniversityAcademic/Hospital1011982
Chinese University of Hong KongAcademic/Hospital1112005
Clinical Data, Inc.For profit1011982
Federal University of Rio Grande do SulAcademic/Hospital1112013
GeigyFor profit1112000
Gottfried Wilhelm Leibniz Universität HannoverAcademic/Hospital1112015
Government of DenmarkGovernment1012004
Hualien Tzu Chi General HospitalAcademic/Hospital1112024
Johns Hopkins UniversityAcademic/Hospital1011982
43 organizations
Page 1 / 3

Marketing (31)

OrganizationOrg typeRelationshipDate
AbbottFor profitNDA2Nov 15, 1974
Alta PharmaFor profitMKTGJun 19, 1978
American CyanamidFor profitMKTGApr 5, 1982
Avon ProductsFor profitMKTGMay 22, 1984
Chartwell PharmaceuticalsFor profitMKTGMar 11, 2010
CibaFor profitNDAJun 1, 1959
HikmaFor profitMKTGApr 16, 2010
HikmaFor profitSYNApr 16, 2010
Leading Pharma LlcFor profitMKTGOct 24, 2012
Leading Pharma LlcFor profitSYNOct 24, 2012
LederleFor profitMKTGApr 5, 1982
LupinFor profitMKTGMar 11, 2010
MallinckrodtFor profitMKTGMay 22, 1984
MylanFor profitMKTGJun 28, 2013
NovartisFor profitNDA2Oct 2, 1959
NovartisFor profitMKTG
Oxford PharmaceuticalsFor profitMKTGFeb 28, 2008
Par PharmaceuticalsFor profitMKTGOct 21, 1983
Rising PharmaceuticalsFor profitMKTGJun 28, 2013
Roxane LaboratoriesFor profitMKTGAug 5, 1977
SandozFor profitMKTGApr 20, 1976
Sanofi-AventisFor profitNDA2Apr 16, 1959
Specgx LlcFor profitNDA2Mar 11, 1973
Specgx LlcFor profitMKTGMay 22, 1984
Strides Pharma ScienceFor profitMKTGOct 21, 1983
Sun PharmaceuticalsFor profitMKTGJun 5, 1990
TevaFor profitMKTGJun 27, 1974
Upsher-Smith LaboratoriesFor profitMKTGFeb 10, 1982
VanguardFor profitMKTGJan 4, 1982
Watson PharmaceuticalsFor profitMKTGOct 16, 1978
West-Ward PharmaceuticalFor profitMKTGApr 16, 2010